These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31300814)

  • 1. Graded Dalbavancin Challenge in a Patient With Severe Vancomycin Hypersensitivity Reaction.
    Ishizuka KT; Tran TK; Ayars AG; Chau AS; Chan JD
    Clin Infect Dis; 2020 Mar; 70(6):1230-1232. PubMed ID: 31300814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Dalbavancin in Vancomycin Allergic Patients: A Case Series.
    Jones BM; Freeman KJ; Cleveland KO; Bland CM
    Clin Ther; 2022 Dec; 44(12):e59-e63. PubMed ID: 36464517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DRESS Syndrome Caused by Cross-reactivity Between Vancomycin and Subsequent Teicoplanin Administration: A Case Report.
    Miyazu D; Kodama N; Yamashita D; Tanaka H; Inoue S; Imakyure O; Hirakawa M; Shuto H; Kataoka Y
    Am J Case Rep; 2016 Aug; 17():625-31. PubMed ID: 27572807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
    Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
    N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Red-man syndrome after vancomycin: potential cross-reactivity with teicoplanin.
    Khurana C; de Belder MA
    Postgrad Med J; 1999 Jan; 75(879):41-3. PubMed ID: 10396588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycopeptide-induced vasculitis--cross-reactivity between vancomycin and teicoplanin.
    Marshall C; Street A; Galbraith K
    J Infect; 1998 Jul; 37(1):82-3. PubMed ID: 9733391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalbavancin: a new lipoglycopeptide antibiotic.
    Bailey J; Summers KM
    Am J Health Syst Pharm; 2008 Apr; 65(7):599-610. PubMed ID: 18359966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of dalbavancin, a novel semisynthetic lipoglycopeptide.
    Kim A; Kuti JL; Nicolau DP
    Expert Opin Investig Drugs; 2007 May; 16(5):717-33. PubMed ID: 17461743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of teicoplanin adverse drug reactions among patients with vancomycin-associated adverse drug reactions and its risk factors.
    Kim BK; Kim JH; Sohn KH; Kim JY; Chang YS; Kim SH
    Korean J Intern Med; 2020 May; 35(3):714-722. PubMed ID: 31722513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teicoplanin-induced hypersensitivity syndrome with a preceding vancomycin-induced neutropenia: a case report and literature review.
    Hsiao SH; Chen HH; Chou CH; Lin WL; Liu Yeh PY; Wu TJ
    J Clin Pharm Ther; 2010 Dec; 35(6):729-32. PubMed ID: 21054466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.
    Jones RN; Sader HS; Fritsche TR; Hogan PA; Sheehan DJ
    J Clin Microbiol; 2006 Jul; 44(7):2622-5. PubMed ID: 16825398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative safety of teicoplanin and vancomycin.
    Wood MJ
    J Chemother; 2000 Nov; 12 Suppl 5():21-5. PubMed ID: 11131960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Reaction during dalbavancin infusion: About one case].
    Valentin B; Dartus J; Trouillez T; Gaboriau L; Loiez C; Dezèque H; Odou P; Décaudin B; Migaud H; Genay S; Senneville E
    Therapie; 2021; 76(5):488-490. PubMed ID: 32723578
    [No Abstract]   [Full Text] [Related]  

  • 14. A case of hypersensitivity syndrome to both vancomycin and teicoplanin.
    Kwon HS; Chang YS; Jeong YY; Lee SM; Song WJ; Kim HB; Kim YK; Cho SH; Kim YY; Min KU
    J Korean Med Sci; 2006 Dec; 21(6):1108-10. PubMed ID: 17179696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalbavancin: a review for dermatologists.
    Scheinfeld N
    Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies.
    Dunne MW; Sahm D; Puttagunta S
    Ann Clin Microbiol Antimicrob; 2015 Apr; 14():19. PubMed ID: 25885674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy.
    Hsiao SH; Chou CH; Lin WL; Lee EJ; Liao LH; Chang HJ; Yeh PY; Lin CY; Wu TJ
    J Clin Pharm Ther; 2012 Jun; 37(3):296-300. PubMed ID: 22017186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.
    Werth BJ; Jain R; Hahn A; Cummings L; Weaver T; Waalkes A; Sengupta D; Salipante SJ; Rakita RM; Butler-Wu SM
    Clin Microbiol Infect; 2018 Apr; 24(4):429.e1-429.e5. PubMed ID: 28782651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014).
    Jones RN; Rhomberg PR; Mendes RE
    Diagn Microbiol Infect Dis; 2016 Oct; 86(2):249-51. PubMed ID: 27502927
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.